Company history

Astellas began on 1 April 2005, when Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical merged. The logic was arithmetic. Japan cut official drug prices every two years, so the domestic market would not grow; in the same years the American and European majors were combining to lift their research budgets. Ranked third and fifth at home, neither company could keep earning back the cost of discovering a drug on its own. Their strengths, usefully, barely overlapped — Yamanouchi in urology and cardiovascular medicine, Fujisawa in transplantation and immunology. The combined firm had drug sales of roughly ¥800 billion, second in Japan behind Takeda and seventeenth in the world, about 2,400 sales representatives, and an R&D budget of $1.3B (¥145bn) — the largest in the country, and past the ¥100 billion mark then treated as the price of staying in the game. Takenaka Toichi, who became the first president, put it plainly at the time: ¥70 billion was not enough, and ¥100 billion was the rough minimum.

Duplication was stripped out from the first year. Formulation plants were consolidated into Astellas Tokai in April 2005 and bulk drug manufacturing into Astellas Pharma Chemicals a year later. Management ran through nine divisions reporting to the president, with heads drawn deliberately from both predecessor companies, and research was reorganized by function rather than by origin. The scale change was immediate: Yamanouchi alone had ended its final year (March 2005) with revenue of ¥447.1 billion and 7,196 employees; the first Astellas year came in at ¥879.3 billion and 14,965.

The more consequential move came in April 2008, when Astellas set up Astellas Pharma Global Development in the United States and put its development headquarters there. Takenaka had refused equity-linked approaches from foreign majors before the merger precisely because he doubted they would let research continue in Japan. What he chose three years later was a split: keep discovery at home, move the command post for clinical development into the largest market in the world. For a major Japanese pharmaceutical company at the time, that was a long step.

In June 2010 Astellas bought OSI Pharmaceuticals for about $4.6B (¥400bn) — the largest cross-border deal in its short history, and one begun without the target’s consent, the offer rising from $52 to $57.50 a share before agreement. OSI brought the lung-cancer drug Tarceva and, far more importantly, the prostate-cancer compound that became XTANDI (enzalutamide). With it, a company whose centre of gravity had been urology and transplantation tilted decisively toward oncology, and toward the United States as its main battlefield.

The presidency passed from Nogimori Masafumi to Hatanaka Yoshihiko in the same month, handing the post-deal integration to a research-and-development man. Under Hatanaka the sales subsidiaries opened from 2008 onward — India, Brazil, Australia, Singapore, Malaysia — were brought fully into service, replacing distributors with the group’s own salesforce as far as the emerging markets. The American direct-sales organization did double duty as the launch vehicle for XTANDI.

XTANDI became a standard of care in castration-resistant prostate cancer and carried the numbers with it. Revenue of ¥969.4 billion in the year to March 2012 reached ¥1,164.5 billion by March 2014 and ¥1,372.7 billion by March 2016, with net profit of $1.8B (¥194bn) — the best result since the merger. The urology salesforce Yamanouchi had spent decades building meshed with a prostate drug, which is much of why the US launch moved so fast. It also meant that at peak, more than 30% of group sales came from one product. The hedging began even as the peak arrived: a biopharma joint venture with Amgen started work in 2013, Ocata Therapeutics (ophthalmic cell therapy) was bought in February 2016, and Ganymed Pharmaceuticals — with the Claudin18.2 antibody zolbetuximab — that December.

Astellas bought the Belgian firm Ogeda in May 2017, adding women’s health, and a month later Yasukawa Kenji became president. He made explicit what the previous decade had been doing implicitly: the company could not win on in-house research alone, and taking in outside innovation would be a standing system rather than an occasional tactic. Profit was still strong — ¥218.7 billion in the year to March 2017 — but the market had already priced in the question of what happens when XTANDI loses US exclusivity, and thickening the pipeline from outside was the answer on offer.

The purchases came quickly: Mitobridge (mitochondrial disease) in January 2018, Potenza Therapeutics (cancer immunology) that December, and in January 2020 Audentes Therapeutics, which took Astellas into gene therapy. Audentes was the boldest of them — an adeno-associated-virus therapy for neuromuscular disease, AT132, in a field where even the manufacturing process was unsettled. It did not go well. Adverse events in the trial combined with process problems to stall the programme; the subsidiary was renamed Astellas Gene Therapies and its governance rebuilt. Revenue slipped to ¥1,249.5 billion in the year to March 2021 with net profit of ¥120.6 billion, and the contribution from the new modalities remained hard to see.

What Astellas could point to were successor products in waiting. Padcev (urothelial cancer), Xospata (AML) and Evrenzo (renal anaemia) were designated focus products; zolbetuximab, inherited from Ganymed, produced promising gastric-cancer data on the way to becoming VYLOY; fezolinetant, inherited from Ogeda, moved toward US filing as VEOZAH. Yasukawa paired the external programme with an internal one, naming the elimination of in-house barriers to innovation as his own job. The structural difficulty was time: each new modality needed its own long run of development, manufacturing and launch before anything reached the income statement, and filling that gap defined his tenure.

Okamura Naoki, president from June 2022, kept his predecessor’s course and raised the stakes. In July 2023 Astellas bought IVERIC bio for about $5.7B (¥800bn) — twice what OSI had cost — for IZERVAY, a treatment for geographic atrophy in age-related macular degeneration. Ophthalmology was thereby promoted alongside oncology, transplantation and urology as a core area. The deal put $6.3 billion of intangible assets and $251 million of goodwill on the balance sheet, and started $5.2 billion of amortization tied to IZERVAY.

The bill arrived at once. Revenue for the year to March 2024 rose 5.6% to ¥1,603.7 billion, but acquisition costs together with ¥56.3 billion of impairments on AT808 and Evrenzo cut net profit to $112.2M (¥17bn), down 82.7%. Okamura told analysts that several development programmes had been discontinued and that the pipeline would be rebuilt around lower-risk in-licensed assets. Nineteen years after the merger, a company spending on the largest scale it ever had was simultaneously writing off what it had bought — and the serial-acquisition strategy itself was on trial.

From the following year the work changed from buying to earning. The Sustainable Margin Transformation programme launched in 2024 targets ¥120–150 billion of cost optimization across the four years to March 2028 — up to $990.1M (¥150bn) — largely by running global clinical trials in-house instead of outsourcing them, with a core operating margin of 30% as the goal for the year to March 2028. The clock is set by XTANDI, whose US exclusivity is expected to end in 2027. The recovery has been fast: revenue of ¥1,912.3 billion and net profit of ¥50.7 billion in the year to March 2025, then ¥2,139.2 billion of revenue, ¥382.6 billion of operating profit and ¥291.5 billion of net profit in the year to March 2026 — seventeen times the trough two years earlier, and double the ¥1 trillion the merged company set as its target in 2005. Whether the acquired assets can actually replace XTANDI is the question 2027 will answer.